FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377011357> ?p ?o ?g. }

• W4377011357 endingPage "e001607" @default.
• W4377011357 startingPage "e001607" @default.
• W4377011357 abstract "Introduction Bronchodilators, including long-acting muscarinic antagonists (LAMA) and long-acting beta 2 agonists (LABA), are the main treatments for chronic obstructive pulmonary disease (COPD). The efficacy of triple therapy (inhaled corticosteroids/LAMA/LABA) has also been reported. However, the effect of triple therapy on patients with mild-to-moderate COPD has not yet been clarified. This study aims to investigate the safety and efficacy of triple therapy, compared with LAMA/LABA combination therapy, for lung function and health-related quality of life in patients with mild-to-moderate COPD and identify baseline characteristics and biomarkers to predict responders and non-responders to triple therapy. Methods and analysis This is a multicentre, prospective, open-label, randomised, parallel-group study. Mild-to-moderate patients with COPD will be randomised to receive fluticasone furoate/umeclidinium/vilanterol or umeclidinium/vilanterol for 24 weeks. A total of 668 patients will be enrolled from March 2022 to September 2023 from 38 sites in Japan. The primary endpoint is the change in the trough forced expiration volume in 1 s after 12 weeks of treatment. Secondary endpoints are responder rates based on the COPD assessment test score and the St. George’s Respiratory Questionnaire total score after 24 weeks of treatment. The safety endpoint is the occurrence of any adverse events. We will also investigate safety in terms of changes in microbial colonisation in sputum and antimycobacterium avium complex antibodies. Ethics and dissemination The study protocol and informed consent documents were approved by the Saga University Clinical Research Review Board (approval number: CRB7180010). Written informed consent will be obtained from all patients. Recruitment of the patients began in March 2022. The results will be disseminated through scientific peer-reviewed publications and domestic and international medical conferences. Trial registration numbers UMIN000046812 and jRCTs031190008." @default.
• W4377011357 created "2023-05-19" @default.
• W4377011357 creator A5003302663 @default.
• W4377011357 creator A5014459642 @default.
• W4377011357 creator A5031169738 @default.
• W4377011357 creator A5031981364 @default.
• W4377011357 creator A5036516013 @default.
• W4377011357 creator A5043936285 @default.
• W4377011357 creator A5048335326 @default.
• W4377011357 creator A5048500471 @default.
• W4377011357 creator A5054394679 @default.
• W4377011357 creator A5076885089 @default.
• W4377011357 creator A5087568541 @default.
• W4377011357 date "2023-05-01" @default.
• W4377011357 modified "2023-09-30" @default.
• W4377011357 title "Efficacy and safety of once-daily single-inhaler triple therapy for mild-to-moderate chronic obstructive pulmonary disease: a study protocol for a randomised and interventional study" @default.
• W4377011357 cites W1905422379 @default.
• W4377011357 cites W1913610488 @default.
• W4377011357 cites W1997229662 @default.
• W4377011357 cites W2069826751 @default.
• W4377011357 cites W2075844360 @default.
• W4377011357 cites W2105632276 @default.
• W4377011357 cites W2116141140 @default.
• W4377011357 cites W2116954144 @default.
• W4377011357 cites W2119767177 @default.
• W4377011357 cites W2129633626 @default.
• W4377011357 cites W2153284508 @default.
• W4377011357 cites W2157968241 @default.
• W4377011357 cites W2399290487 @default.
• W4377011357 cites W2510740867 @default.
• W4377011357 cites W2558984684 @default.
• W4377011357 cites W2604577460 @default.
• W4377011357 cites W2613136430 @default.
• W4377011357 cites W2663190063 @default.
• W4377011357 cites W2792516233 @default.
• W4377011357 cites W2802221596 @default.
• W4377011357 cites W2888740299 @default.
• W4377011357 cites W2891482814 @default.
• W4377011357 cites W2897953679 @default.
• W4377011357 cites W2919543584 @default.
• W4377011357 cites W2920797638 @default.
• W4377011357 cites W2962085649 @default.
• W4377011357 cites W2963868005 @default.
• W4377011357 cites W2993660735 @default.
• W4377011357 cites W3003551360 @default.
• W4377011357 cites W3040902964 @default.
• W4377011357 cites W3097445918 @default.
• W4377011357 cites W3104388357 @default.
• W4377011357 cites W3107279930 @default.
• W4377011357 cites W3112576098 @default.
• W4377011357 cites W3167829426 @default.
• W4377011357 cites W3176486399 @default.
• W4377011357 cites W3207588227 @default.
• W4377011357 cites W4291000629 @default.
• W4377011357 cites W4322495781 @default.
• W4377011357 doi "https://doi.org/10.1136/bmjresp-2022-001607" @default.
• W4377011357 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37197795" @default.
• W4377011357 hasPublicationYear "2023" @default.
• W4377011357 type Work @default.
• W4377011357 citedByCount "0" @default.
• W4377011357 crossrefType "journal-article" @default.
• W4377011357 hasAuthorship W4377011357A5003302663 @default.
• W4377011357 hasAuthorship W4377011357A5014459642 @default.
• W4377011357 hasAuthorship W4377011357A5031169738 @default.
• W4377011357 hasAuthorship W4377011357A5031981364 @default.
• W4377011357 hasAuthorship W4377011357A5036516013 @default.
• W4377011357 hasAuthorship W4377011357A5043936285 @default.
• W4377011357 hasAuthorship W4377011357A5048335326 @default.
• W4377011357 hasAuthorship W4377011357A5048500471 @default.
• W4377011357 hasAuthorship W4377011357A5054394679 @default.
• W4377011357 hasAuthorship W4377011357A5076885089 @default.
• W4377011357 hasAuthorship W4377011357A5087568541 @default.
• W4377011357 hasBestOaLocation W43770113571 @default.
• W4377011357 hasConcept C126322002 @default.
• W4377011357 hasConcept C1862650 @default.
• W4377011357 hasConcept C197934379 @default.
• W4377011357 hasConcept C203092338 @default.
• W4377011357 hasConcept C2776042228 @default.
• W4377011357 hasConcept C2776780178 @default.
• W4377011357 hasConcept C2777419714 @default.
• W4377011357 hasConcept C2779028295 @default.
• W4377011357 hasConcept C2780261241 @default.
• W4377011357 hasConcept C2780911369 @default.
• W4377011357 hasConcept C535046627 @default.
• W4377011357 hasConcept C71924100 @default.
• W4377011357 hasConceptScore W4377011357C126322002 @default.
• W4377011357 hasConceptScore W4377011357C1862650 @default.
• W4377011357 hasConceptScore W4377011357C197934379 @default.
• W4377011357 hasConceptScore W4377011357C203092338 @default.
• W4377011357 hasConceptScore W4377011357C2776042228 @default.
• W4377011357 hasConceptScore W4377011357C2776780178 @default.
• W4377011357 hasConceptScore W4377011357C2777419714 @default.
• W4377011357 hasConceptScore W4377011357C2779028295 @default.
• W4377011357 hasConceptScore W4377011357C2780261241 @default.
• W4377011357 hasConceptScore W4377011357C2780911369 @default.
• W4377011357 hasConceptScore W4377011357C535046627 @default.
• W4377011357 hasConceptScore W4377011357C71924100 @default.
• W4377011357 hasFunder F4320307773 @default.

• next